Tag: Takeda

Takeda – First Private Pharma Company to Pledge for Global Fund Replenishment

takeda
Takeda Pharmaceutical Company Limited became the first private sector company to announce a financial commitment to the Global Fund’s Sixth Replenishment. The new pledge, consisting of JP ¥ 1 billion ...

Takeda’s Entyvio® Received Approval in Japan

drugsapproved
Takeda Pharmaceutical Company Limited announced that it has obtained approval from the Ministry of Health, Labour and Welfare (MHLW) for an additional indication for Entyvio® (generic name: vedolizuma...

FDA Approved Takeda’s GATTEX

Takeda Pharmaceuticals, announced today that the US Food and Drug Administration (FDA) approved extending the indication of GATTEX (teduglutide) for injection to pediatric patients 1 year of age and o...

Takeda Chair in Global Child Health Established at LSHTM

Takeda Pharmaceutical Company Limited and the London School of Hygiene & Tropical Medicine (LSHTM) announced the establishment of the Takeda Chair in Global Child Health, endowed by a £3 million d...

Frazier Healthcare Partners and Takeda Veterans to Develop GI Drug Vonoprazan

Marking the partners' second company launch with a Takeda-discovered asset, Frazier Healthcare Partners and the Japanese pharma launched Phathom with rights to gastrointestinal drug vonoprazan. The st...

Takeda Announced Financial Results for 2018

takeda
− Excellent FY2018 results driven by key growth products and strict Opex discipline, with Legacy Takeda greatly exceeding original guidance and absorbing Shire acquisition-related costs − In FY20...

FDA Accepts Takeda’s Application for a Subcutaneous Formulation of Vedolizumab

fda
Takeda Pharmaceutical Company Limited (“Takeda”) announced that the U.S. Food & Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for a subcutaneous (SC) form...

Novartis Agreed to Pay $3.4 billion for Eye Drug Assets

Novartis AG agreed to pay $3.4 billion for eye-disease medicines that Takeda Pharmaceutical Co. is selling to shed debt after its $62 billion acquisition of Shire Plc. The main product in the deal ...

Takeda Enters Strategic Alliance with Skyhawk

takeda
US-based Skyhawk Therapeutics has formed a strategic alliance with Takeda Pharmaceutical to discover and develop small molecule drug candidates for multiple targets across neurodegenerative diseases. ...

Takeda Opened Global Research Facility in San Diego

takeda
Japan-based Takeda Pharmaceutical has opened a new 165,000ft² global research facility in San Diego of California, US. With over 250 employees, the San Diego research center will focus on lever...

Takeda Completed the Localization of Advate in Russia

Takeda completed the localization of the production of Advate (Octocog alpha) medicine, intended for the treatment of patients with hemophilia A, at the Moscow-based Biocad plant. This was told to Kom...

Gene Editing Platform Developer Emendo Inks Licensing Option Agreement with Takeda

takeda hq tokyo
Emendo Biotherapeutics Inc today announced that the company signed a licensing option agreement with Takeda Pharmaceutical Company Limited. As part of the transaction, Emendo will receive an inves...

LCB Partners with Takeda in Immuno-Oncology Field

LegoChem Biosciences, Inc. (LCB) announced that it has entered a research collaboration and license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for the development of antibody-drug...

First Licensing Agreement between Petra and Takeda

Petra Pharma Corporation ("Petra"), a leader in phosphoinositide (PI) signaling pathway inhibition, announced it has secured a global license from Takeda Pharmaceutical Company Limited ("Takeda") to d...

Takeda Looks to Cut Debt after M&A Shire

takeda hq tokyo
Takeda Pharmaceutical Co. is planning a sale of its Tachosil brand of surgical patches and sealants as it looks to cut debt after its $62 billion takeover of Shire Plc, people familiar with the matter...

EC Approved Takeda’s ADCETRIS 

ADCETRIS in Combination with AVD (Adriamycin, Vinblastine and Dacarbazine) Demonstrated 29-Percent Reduction in the Risk of Progression, Death or Need for Additional Anticancer Therapy for CD30+ Stage...